192.50
4.90 (2.61%)
| Previous Close | 187.60 |
| Open | 188.00 |
| Volume | 1,871,947 |
| Avg. Volume (3M) | 1,273,591 |
| Market Cap | 13,953,626,112 |
| Price / Earnings (TTM) | 34.01 |
| Price / Earnings (Forward) | 17.09 |
| Price / Sales | 3.36 |
| Price / Book | 3.31 |
| 52 Weeks Range | |
| Earnings Date | 29 Apr 2026 |
| Profit Margin | 10.29% |
| Operating Margin (TTM) | 14.02% |
| Diluted EPS (TTM) | 5.50 |
| Quarterly Revenue Growth (YOY) | -1.80% |
| Quarterly Earnings Growth (YOY) | -11.20% |
| Total Debt/Equity (MRQ) | 3.12% |
| Current Ratio (MRQ) | 1.21 |
| Operating Cash Flow (TTM) | 762.24 M |
| Levered Free Cash Flow (TTM) | 630.04 M |
| Return on Assets (TTM) | 6.72% |
| Return on Equity (TTM) | 10.84% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Align Technology, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 4.0 |
| Average | 0.25 |
|
Align Technology is the leading manufacturer of clear aligners. Invisalign, its main product, was approved by the Food and Drug Administration in 1998 and has since dominated, controlling over 90% of the market. Invisalign can treat roughly 90% of all malocclusion cases (misaligned teeth), and there are over 230,000 Invisalign-trained dentists and orthodontists. In 2022, Invisalign treated over 2 million cases, or roughly 10% of all orthodontic cases for the year, and it has treated over 14 million patients since its launch. Align also sells intraoral scanners under the brand iTero, which captures digital impressions of patients’ teeth and illustrates treatment plans. Over 85% of Invisalign cases are submitted by digital scans, and iTero scans make up over half of these scans. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Mid Core |
| % Held by Insiders | 6.68% |
| % Held by Institutions | 94.17% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 220.00 (Piper Sandler, 14.29%) | Buy |
| Median | 200.00 (3.90%) | |
| Low | 169.00 (Morgan Stanley, -12.21%) | Hold |
| Average | 194.89 (1.24%) | |
| Total | 6 Buy, 3 Hold | |
| Avg. Price @ Call | 174.53 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HSBC | 09 Feb 2026 | 200.00 (3.90%) | Buy | 192.50 |
| Evercore ISI Group | 05 Feb 2026 | 200.00 (3.90%) | Buy | 175.62 |
| Morgan Stanley | 05 Feb 2026 | 169.00 (-12.21%) | Hold | 175.62 |
| Piper Sandler | 05 Feb 2026 | 220.00 (14.29%) | Buy | 175.62 |
| Stifel | 05 Feb 2026 | 210.00 (9.09%) | Buy | 175.62 |
| UBS | 05 Feb 2026 | 185.00 (-3.90%) | Hold | 175.62 |
| Wells Fargo | 05 Feb 2026 | 200.00 (3.90%) | Buy | 175.62 |
| Mizuho | 20 Jan 2026 | 200.00 (3.90%) | Buy | 165.55 |
| Barclays | 09 Dec 2025 | 170.00 (-11.69%) | Hold | 159.00 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |